Form 4: Exact Sciences EVP Sarah Condella Reports Stock Transactions

Sarah Condella, EVP of Human Resources at Exact Sciences, reports the vesting and disposal of restricted stock units for tax withholding.

Summary

• On February 25, 2025, Sarah Condella, EVP of Human Resources at Exact Sciences Corp, reported transactions involving common stock and restricted stock units.
• 3,954 shares of common stock were acquired upon the vesting of restricted stock units.
• 1,859 shares were disposed of to cover tax withholding obligations at a price of $51.28 per share.
• Following these transactions, Ms. Condella directly owns 78,438 shares of common stock and indirectly owns 6,100 shares held in a 401(k) plan.
• She also holds 23,817 restricted stock units that vest in four equal annual installments beginning on February 27, 2026.
• Additionally, she holds 3,955 restricted stock units from a grant on February 25, 2022, vesting in four equal annual installments from the grant date.
• Ms. Condella also holds an additional 106,865 vested and unvested options to purchase shares of Common Stock and restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral report on stock transactions by an executive, with no inherent positive or negative implications for the company's overall outlook.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's a standard practice for executives at publicly traded companies like Exact Sciences.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, including Exact Sciences, and are comparable to similar filings from executives at companies like Guardant Health, Illumina, and Myriad Genetics.
• The vesting schedules and tax withholding practices are also typical for equity compensation plans in the biotechnology and diagnostics industries.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.
• Employees may be interested in the details of executive compensation, but the direct impact is limited.

Key Dates